Related Experiment Video
Updated: Jan 13, 2026

Recurrent Escherichia coli Urinary Tract Infection Triggered by Gardnerella vaginalis Bladder Exposure in Mice
Published on: December 4, 2020
Histamine-Producing Intestinal Dysbiosis and Its Role in Lower Urinary Tract Infections and Irritable Bowel Syndrome
Florina Ruța1, Călin Avram2, Elena Mardale3
1Department of Community Nutrition and Food Safety, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania.
Abstract:
Background: Lower urinary tract infections (LUTIs) and irritable bowel syndrome (IBS) have been associated with histamine-producing gut dysbiosis, characterized by an overgrowth of histaminogenic bacteria and opportunistic fungi. This study examines the relationship between histaminogenic microbial imbalance, dietary factors, and LUTIs in women with IBS, emphasizing the potential nutritional contributions to microbiota modulation. Methods: A cohort of 188 women was evaluated by analyzing the intestinal microbiota associated with sporadic and recurrent lower urinary tract infections and irritable bowel syndrome, along with a questionnaire on risky eating behaviors. Results: Dysbiosis was associated with an overgrowth of histamine-producing bacteria (Escherichia coli, Enterobacter spp., Clostridium spp.) and Candida albicans, along with a depletion of protective taxa (Lactobacillus, Bifidobacterium). Dysbiosis, characterized by an increase in histamine-producing bacteria (Escherichia coli, Enterobacter spp., Clostridium spp.) and Candida albicans, together with a depletion of protective taxa (Lactobacillus, Bifidobacterium), has been associated with lower urinary tract infections and irritable bowel syndrome. Regarding the increase in histaminogenic flora, significant associations with dietary factors concerned only the frequent consumption of fast food. Conclusions: These findings highlight the role of histamine-driven dysbiosis in sustaining chronic inflammation and susceptibility to LUTIs and IBS, supporting microbiota modulation as a potential preventive and therapeutic strategy.
Related Concept Videos
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Urinary Tract Infection II: Pathophysiology
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Urinary Tract Infection I: Introduction
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Irritable Bowel Syndrome III: Medical and Nursing Management

